Jay Olson
Stock Analyst at Oppenheimer
(4.26)
# 403
Out of 5,148 analysts
250
Total ratings
46.04%
Success rate
18.97%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIOA BioAge Labs | Initiates: Outperform | $60 | $21.71 | +176.37% | 1 | Feb 25, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $540 | $486.03 | +11.10% | 1 | Feb 13, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $21 → $23 | $22.81 | +0.83% | 16 | Feb 6, 2026 | |
| BIIB Biogen | Maintains: Outperform | $205 → $225 | $188.05 | +19.65% | 26 | Jan 30, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $75 → $150 | $101.62 | +47.61% | 10 | Jan 27, 2026 | |
| CHRS Coherus Oncology | Initiates: Outperform | $10 | $1.65 | +506.06% | 1 | Jan 22, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $250 → $750 | $330.59 | +126.87% | 3 | Dec 15, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $28 → $58 | $42.03 | +38.00% | 4 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $600 → $650 | $435.62 | +49.21% | 12 | Nov 20, 2025 | |
| IBIO iBio, Inc. | Initiates: Outperform | $5 | $2.69 | +85.87% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $90 | $81.96 | +9.81% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $30 | $5.00 | +500.00% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $44 | $5.73 | +667.89% | 4 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $3.68 | +280.43% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.40 | - | 15 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $3.96 | +1,541.41% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $65 | $1.35 | +4,714.81% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $1.74 | +647.13% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $68.36 | +31.66% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $21.00 | +100.00% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $41.03 | -19.57% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $15.44 | +159.07% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $4.95 | +304.04% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $5.72 | +424.48% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $100.04 | -18.03% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $30.05 | -66.72% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $33.34 | +313.92% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.71 | +195.20% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $385.70 | -1.48% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $132.38 | +65.43% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.15 | +458.14% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $4.15 | +333.73% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 | $20.55 | +386.74% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $60.77 | +56.33% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $0.76 | +3,184.72% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.06 | +749.06% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.34 | +37,213.43% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $14.51 | +44.73% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.84 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.44 | +381.65% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.24 | - | 3 | Jul 11, 2017 |
BioAge Labs
Feb 25, 2026
Initiates: Outperform
Price Target: $60
Current: $21.71
Upside: +176.37%
Vertex Pharmaceuticals
Feb 13, 2026
Upgrades: Outperform
Price Target: $540
Current: $486.03
Upside: +11.10%
ACADIA Pharmaceuticals
Feb 6, 2026
Maintains: Perform
Price Target: $21 → $23
Current: $22.81
Upside: +0.83%
Biogen
Jan 30, 2026
Maintains: Outperform
Price Target: $205 → $225
Current: $188.05
Upside: +19.65%
Revolution Medicines
Jan 27, 2026
Maintains: Outperform
Price Target: $75 → $150
Current: $101.62
Upside: +47.61%
Coherus Oncology
Jan 22, 2026
Initiates: Outperform
Price Target: $10
Current: $1.65
Upside: +506.06%
Praxis Precision Medicines
Dec 15, 2025
Maintains: Outperform
Price Target: $250 → $750
Current: $330.59
Upside: +126.87%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $28 → $58
Current: $42.03
Upside: +38.00%
Madrigal Pharmaceuticals
Nov 20, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $435.62
Upside: +49.21%
iBio, Inc.
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $2.69
Upside: +85.87%
Oct 8, 2025
Maintains: Outperform
Price Target: $84 → $90
Current: $81.96
Upside: +9.81%
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $5.00
Upside: +500.00%
Aug 11, 2025
Maintains: Outperform
Price Target: $48 → $44
Current: $5.73
Upside: +667.89%
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $3.68
Upside: +280.43%
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $9.40
Upside: -
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $3.96
Upside: +1,541.41%
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $1.35
Upside: +4,714.81%
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.74
Upside: +647.13%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $68.36
Upside: +31.66%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $21.00
Upside: +100.00%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $41.03
Upside: -19.57%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $15.44
Upside: +159.07%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $4.95
Upside: +304.04%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $5.72
Upside: +424.48%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $100.04
Upside: -18.03%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $30.05
Upside: -66.72%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $33.34
Upside: +313.92%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $2.71
Upside: +195.20%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $385.70
Upside: -1.48%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $132.38
Upside: +65.43%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.15
Upside: +458.14%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $4.15
Upside: +333.73%
May 15, 2024
Maintains: Outperform
Price Target: $100
Current: $20.55
Upside: +386.74%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $60.77
Upside: +56.33%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $0.76
Upside: +3,184.72%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.06
Upside: +749.06%
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.34
Upside: +37,213.43%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $14.51
Upside: +44.73%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.84
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.44
Upside: +381.65%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $2.24
Upside: -